Nephrocare Health Services Limited has filed a writ petition before the Hon'ble High Court of Jammu & Kashmir and Ladakh at Srinagar on April 02, 2026, challenging GST orders totaling ₹2.51 crore. The company disclosed this development under Regulation 30 of SEBI Listing Regulations through case number WP(C)/646/2026.

GST Demand Breakdown

The GST authorities have raised a comprehensive demand against the company following alleged discrepancies in tax filings:

Timeline of Dispute

The litigation originated from a Show Cause Notice dated September 18, 2024 issued under Section 73 of the CGST/J&K GST Act, 2017. The notice alleged a mismatch between turnover reported in Form 26AS and GST returns (GSTR-1) for FY 2020-21.

Key Chronological Events:

• September 18, 2024: Show Cause Notice issued
• January 13, 2025: Order-in-Original passed raising demand
• May 24, 2025: Company filed rectification application
• March 6, 2026: Rectification application rejected
• March 7, 2026: Appeal filed against Order-in-Original
• March 12, 2026: Appeal rejected on grounds of delay
• April 02, 2026: Writ petition filed

Company's Defense Position

Nephrocare Health Services submitted detailed replies clarifying that Form 26AS reflects PAN-based turnover across multiple GST registrations, making it incomparable with GST returns filed for specific U.T. of Jammu & Kashmir registration. The company emphasized that its dialysis and allied healthcare services are exempt from GST under applicable notifications.

Recovery Proceedings Initiated

Parallel to the adjudication process, GST authorities initiated recovery proceedings by issuing an attachment notice dated February 9, 2026 to the company's banker for recovery of alleged dues. This prompted the company to challenge both the validity of orders and recovery proceedings through the writ petition.

Financial Impact Assessment

The company stated it is contesting the ₹2.51 crore demand based on legal advice and internal assessment. Management believes the demand is not tenable and expects the matter will not have material impact on operations. The writ petition challenges the Order-in-Original dated January 13, 2025, Order-in-Appeal dated March 12, 2026, and attachment proceedings initiated by GST authorities.

Nephrocare Health Services Limited has formally notified stock exchanges about its upcoming participation in an investor conference, demonstrating the company's commitment to maintaining transparent communication with the investment community.

Conference Details and Schedule

The company has provided comprehensive details about the upcoming investor engagement through an official communication to both BSE Limited and National Stock Exchange of India Limited. The notification, issued under Regulation 30 of SEBI Listing Regulations, outlines the specific arrangements for the investor meetings.

Regulatory Compliance and Information Sharing

The company has emphasized its adherence to regulatory guidelines regarding information disclosure during investor interactions. Company officials have clearly stated that all discussions will be based exclusively on publicly available information, ensuring compliance with securities regulations.

Key compliance aspects include:

• No unpublished price sensitive information (UPSI) will be discussed
• All interactions will follow SEBI Listing Regulations guidelines
• The disclosure is available on the company's official website at www.nephroplus.com
• Potential schedule changes may occur due to exigencies from either the host or company

Corporate Communication Framework

The notification was signed by Kishore Kathri, Company Secretary & Compliance Officer, demonstrating the company's structured approach to corporate governance. The communication was digitally signed and dated March 16, 2026, providing a clear timeline for the advance notice to investors and regulatory authorities.

This investor conference represents part of Nephrocare Health Services Limited's ongoing efforts to engage with analysts and institutional investors, providing them with opportunities to gain insights into the company's operations and strategic direction through formal, regulated channels.